Generalisations on benefits of aspirin are dangerousBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7260.569 (Published 02 September 2000) Cite this as: BMJ 2000;321:569
- Dan Quinlan, research fellow (firstname.lastname@example.org),
- Ander Cohen, vascular physician and epidemiologist
- Department of Academic Medicine, Guy's, King's and St Thomas's School of Medicine and Dentistry, London SE5 9PJ
EDITOR—The publication of the pulmonary embolism prevention (PEP) trial has created considerable interest in the medical and lay press about the optimal thromboprophylactic strategy to minimise the substantial morbidity and mortality experienced by patients with hip fractures.1 Minerva's interpretation of the trial is misleading,2 and we wish to counter each of her four claims.
Firstly, the claim that the trial showed clearly that aspirin prevents deep vein thrombosis and pulmonary embolism and saves lives is misleading. Although the primary efficacy end …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial